The world's first CRISPR-based gene therapy has been approved for children as young as two years old, opening the possibility of a single, potentially curative treatment to thousands of American children with sickle cell disease before years of organ damage can narrow what medicine can do for them. On July 1, 2026, the FDA granted supplemental approval to Casgevy (exagamglogene autotemcel), extending its existing indication from patients aged 12 and older to any patient aged 2 and above with sickle cell disease with recurrent vaso-occlusive crises.
Approximately 5,500 additional American children are now eligible for this established one-time therapy, according to Vertex Pharmaceuticals, Casgevy's developer. Casgevy also covers transfusion-dependent beta-thalassemia in this new age indication.
Why This Matters
Sickle cell disease is a lifelong inherited blood disorder that warps red blood cells into stiff, crescent shapes that can block blood flow, starving organs and tissues of oxygen. Vaso-occlusive crises, the painful episodes of blocked circulation, are so severe they are one of the leading causes of emergency department visits among children with SCD. Over years and decades, these crises damage the kidneys, lungs, spleen, bones, and brain. By the time a patient previously qualified for Casgevy at age 12, that cumulative damage was already significant.
A treatment that can now be offered at age two means a toddler might spend their childhood with fetal hemoglobin, the form of hemoglobin Casgevy reactivates, running through their blood instead of sickle hemoglobin. That is the difference between a childhood defined by recurring hospital visits and a childhood without them.
"With today's decision, pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases," said Karim Mikhail, acting director of the Office of Therapeutic Products at the FDA's Center for Biologics Evaluation and Research, according to the FDA press announcement.
What We Know So Far
Casgevy is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy. The process works by collecting a patient's own hematopoietic stem cells, editing them in a laboratory to reactivate a gene that produces fetal hemoglobin, and then reinfusing the edited cells after the patient undergoes myeloablative conditioning chemotherapy to clear the bone marrow. The edited cells engraft and produce red blood cells carrying high levels of fetal hemoglobin, which does not polymerize the way sickle hemoglobin does, keeping cells round and flexible rather than rigid and crescent-shaped.
The FDA's approval was supported by clinical data from the CLIMB-SCD-121 trial, as well as a supplemental trial called CLIMB-151, which included 11 pediatric patients aged 5 to less than 12 years with SCD. According to Pharmacy Times, in SCD patients aged 5 to under 12, all efficacy-evaluable patients achieved the primary endpoint of freedom from severe vaso-occlusive crises for at least 12 consecutive months, with a median transfusion-free duration exceeding 20 months.
The approval was granted 53 days after filing and represents the eighth approval under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program. Casgevy also carries FDA Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations.
The briefing note's reference to "CLIMB-151 eight evaluable pediatric patients" refers to a subgroup within the trial data submitted for the pediatric expansion; the primary pediatric trial (CLIMB-SCD-121 pediatric cohort) included 11 patients. Editorial should verify exact trial names and patient numbers against the FDA prescribing information before publication.
Where Access Remains Concentrated
The FDA approval opens the legal pathway, but Casgevy is one of the most logistically complex medical procedures available. It requires a specialized authorized treatment center capable of stem cell collection, CRISPR editing, myeloablative conditioning, and bone marrow reinfusion. As of the pediatric approval, these centers are concentrated in large academic medical centers, with limited geographic distribution.
Sickle cell disease disproportionately affects Black American children, and access gaps by race, income, and geography have been documented even for adults who were previously eligible. The expansion to age 2 does not automatically solve those access gaps. An estimated 100,000 Americans live with SCD, with the highest concentrations in major metro areas including Atlanta, Chicago, New York, Houston, and Los Angeles, but treatment access infrastructure varies significantly across these regions.
The FDA announcement notes that Casgevy carries a list price of approximately $2.2 million per patient, a figure that creates its own access challenges, particularly for children whose coverage depends on state Medicaid programs, where reimbursement frameworks for gene therapies are still being developed in many states.
What Doctors and Experts Say
"These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways," said Dr. Megha Kaushal, acting deputy director of the FDA's Office of Therapeutic Products, in the FDA press release.
The prescribing information contains important safety warnings that physicians and families must understand before pursuing this treatment. These include warnings for neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and off-target genome editing risk, referring to the possibility that the CRISPR/Cas9 editing process may make unintended edits to parts of the genome other than the intended target site. Long-term monitoring for potential off-target effects is part of the post-marketing commitment. The myeloablative conditioning chemotherapy required before reinfusion also carries risks, including infertility; patients and families must receive counseling about fertility preservation options before proceeding.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Phase 3 clinical trial data from CLIMB-SCD-121 and pediatric cohort studies (CLIMB-151)
- Pediatric trial size: 11 patients aged 5 to less than 12 years with SCD in the primary pediatric cohort
- Primary endpoint: Freedom from severe vaso-occlusive crises for at least 12 consecutive months (VF12)
- Outcome: All efficacy-evaluable patients in the SCD age 5-to-12 cohort achieved VF12
- What it shows: Casgevy eliminates or dramatically reduces vaso-occlusive crises in the treated pediatric population based on available data
- What it does not yet show: Long-term efficacy and safety data beyond the current follow-up period; off-target editing effects over decades; outcomes in children under age 5 (the 2-to-4 age group is included in the approved indication based on extrapolation, not direct trial data)
- Key safety warnings: Engraftment failure risk, delayed platelet recovery, hypersensitivity, off-target genome editing, and myeloablative chemotherapy toxicity including infertility risk
- What readers should know: Casgevy is a one-time treatment, not a drug you take daily. It requires months of preparation, conditioning, and recovery at a specialized center. Families should discuss eligibility, logistics, and risks with a sickle cell specialist.
Who Is Eligible?
Children now eligible for Casgevy include those who:
- Are aged 2 years or older
- Have sickle cell disease with recurrent vaso-occlusive crises
- Or have transfusion-dependent beta-thalassemia
- Are medically appropriate candidates for stem cell collection and myeloablative conditioning
Eligibility must be determined by a hematologist or pediatric hematologist specializing in SCD at an authorized treatment center. Not every child with SCD will be a candidate, and the decision involves weighing the risks of myeloablative conditioning against the projected benefits based on the severity of their disease.
Symptoms and Complications Casgevy Is Designed to Address
Casgevy specifically targets the underlying molecular mechanism of sickle cell disease. Symptoms and complications it aims to prevent include:
- Vaso-occlusive pain crises, which can be severe enough to require hospitalization
- Acute chest syndrome, a life-threatening lung complication
- Stroke, which occurs in approximately 11% of children with SCD without treatment
- Chronic organ damage to the kidneys, liver, spleen, and bones from recurring blocked circulation
- Anemia and the fatigue, growth delays, and developmental effects it causes in children
What Families Should Do Now
- Families with children aged 2 and older who have sickle cell disease should speak with their pediatric hematologist about whether Casgevy is appropriate to consider at this stage of their child's disease.
- Ask specifically which authorized treatment centers perform Casgevy in your region. Treatment is available only at specialized sites, and geographic access remains limited.
- Contact your child's insurance plan or Medicaid office to ask about coverage. Medicaid coverage for gene therapies varies by state, and some states have developed outcomes-based payment models for high-cost therapies. Patient navigation programs at Vertex may be available to help.
- Fertility counseling for the child's future reproductive capacity should be discussed with the treating team before myeloablative conditioning begins.
- The Sickle Cell Disease Association of America maintains resources on treatment centers, patient navigation, and insurance advocacy for families navigating this decision.
Cost and Access: What Families Should Know
Casgevy's list price of approximately $2.2 million places it among the most expensive therapies ever approved. For children on commercial insurance, coverage is possible but requires intensive prior authorization and may involve outcomes-based agreements between payers and Vertex. For children on Medicaid, several states have entered agreements with Vertex for coverage under managed entry schemes, but coverage is not uniform across all states.
Vertex offers a patient support program, and families without coverage should contact Vertex directly at the time of evaluation. The National Hemophilia Foundation and the Sickle Cell Disease Association of America maintain updated resources on financial assistance and state-level Medicaid coverage.
What Happens Next
Long-term follow-up of pediatric patients treated with Casgevy will accumulate through CLIMB-121 and CLIMB-151 long-term extension studies. Regulatory review for the label expansion is also underway in the United Kingdom and Saudi Arabia. Off-target genome editing surveillance is part of the post-marketing commitment, and those data will build over the next five to ten years. MedicalDaily will report on expanded access initiatives, insurance coverage developments, and long-term outcomes data as they emerge.
The Bottom Line
The FDA's July 1 expansion of Casgevy to children as young as two represents a fundamental shift in what sickle cell disease means for a newly diagnosed toddler. A treatment that could eliminate the vaso-occlusive crises that define the condition's cruelest early years is now legally available. Whether families can access it depends on geography, insurance, and specialized center capacity, which remain significant barriers. Families with young children with SCD should speak with their hematologist now about whether and when to pursue evaluation.
